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Abstract
Background: Comprehensive evaluation of safety and efficacy of different combina‐
tions	of	direct‐acting	antivirals	(DAAs)	in	liver	transplant	recipients	with	genotype	1	
(GT1)	hepatitis	C	virus	(HCV)	recurrence	remains	limited.	Therefore,	we	performed	
this	systematic	review	and	meta‐analysis	in	order	to	evaluate	the	clinical	outcome	of	
DAA	treatment	in	liver	transplant	patients	with	HCV	GT1	recurrence.
Methods: Studies	were	included	if	they	contained	information	of	12	weeks	sustained	
virologic	response	(SVR12)	after	DAA	treatment	completion	as	well	as	treatment	re‐
lated	complications	for	liver	transplant	recipients	with	GT1	HCV	recurrence.
Results: We	identified	16	studies	comprising	885	patients.	The	overall	pooled	esti‐
mate	proportion	of	SVR12	was	93%	(95%	confidence	interval	 (CI):	0.89,	0.96),	with	
moderate heterogeneity observed (τ2	=	0.01,	P	<	0.01,	I2=75%).	High	tolerability	was	
observed	in	liver	transplant	recipients	reflected	by	serious	adverse	events	(sAEs)	with	
pooled	estimate	proportion	of	4%	(95%	CI:	0.01,	0.07;	τ2	=	0.02,	P	<	0.01,	I2	=	81%).	
For	subgroup	analysis,	a	total	of	five	different	DAA	regimens	were	applied	for	treating	
these	 patients.	 Sofosbuvir/Ledipasvir	 (SOF/LDV)	 led	 the	 highest	 pooled	 estimate	
SVR12	proportion,	followed	by	Paritaprevir/Ritonavir/Ombitasivir/Dasabuvir	(PrOD),	
Daclatasvir	 (DCV)/Simeprevir	 (SMV)	 ±	 Ribavirin	 (RBV),	 and	 SOF/SMV	 ±	 RBV,	
Asunaprevir	(ASV)/DCV.	There	was	a	tendency	for	favoring	a	higher	pooled	SVR12	
proportion	in	patients	with	METAVIR	Stage	F0‐F2	of	97%	(95%	CI:	0.93,	0.99)	com‐
pared	to	85%	(95%	CI:	0.79,	0.90)	for	stage	F3‐F4	(P	<	0.01).	There	was	no	significant	
difference	between	LT	recipients	treated	with	or	without	RBV	(P	=	0.23).
Conclusions: Direct‐acting	antiviral	treatment	is	highly	effective	and	well‐tolerated	
in	liver	transplant	recipients	with	recurrent	GT1	HCV	infection.
K E Y WO RD S
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1  | INTRODUCTION
Liver	 cirrhosis	 and	 hepatocellular	 carcinoma	 (HCC)	 secondary	 to	
hepatitis	 C	 virus	 (HCV)	 infection	 are	 the	 leading	 causes	 for	 liver	
transplantation	(LT)	worldwide.1,2	However,	recurrent	HCV	infection	
post	LT	is	a	unique	and	difficult	medical	dilemma	which	occurs	in	over	
90%	of	patients,	and	severe	recurrent	infection	is	observed	in	nearly	
30%	of	patients	within	3‐5	years.3,4	Thus,	the	allograft	and	recipient	
survival	is	closely	correlated	with	the	successful	eradication	of	HCV.
Until	 very	 recently,	 interferon‐based	 therapy	 was	 the	 only	
treatment	option	and	rate	of	sustained	virologic	response	(SVR)	in	
these	transplant	recipients	was	merely	20%‐30%.5,6 The combina‐
tion	of	direct‐acting	antiviral	(DAA)	agents,	in	the	form	of	a	first‐
generation	protease	inhibitor,	telaprevir	or	boceprevir	doubled	the	
SVR	 rate	at	 the	expense	of	a	 series	of	adverse	events	 (AEs)	and	
serious	 adverse	 events	 (sAEs).7,8	 These	 included	 rashes,	 cytope‐
nias,	allograft	rejection,	severe	anemia,	and	a	mortality	rate	of	9%	
in	one	series.	At	the	end	of	year	of	2013,	the	US	Food	and	Drug	
Administration	(FDA)	and	European	Medicines	Agency	(EMA)	ap‐
provals	of	simeprevir	(SMV)	and	sofosbuvir	(SOF)	heralded	a	new	
era	 in	DAA	therapy	of	HCV‐related	liver	diseases.	Consequently,	
the	launches	of	several	other	second	generation	of	interferon‐free	
DAAs	have	opened	a	new	scenario	which	revolutionized	the	treat‐
ment	of	chronic	HCV	infection	in	the	general	infected	population.	
With	a	very	favorable	safety	profile	and	high	rates	of	SVR	of	over	
95%,9	the	newer	and	all‐oral	DAA‐based	regimens	have	provided	
an	unprecedented	opportunity	 to	 cure	HCV.	Although	HCV	dis‐
ease	 burden	 remains	 substantial	 for	 the	 time	 being,	 however,	 it	
is	 estimated	 that,	 within	 next	 decade,	 most	 patients	 with	 HCV	
infection	would	likely	to	attend	SVR.	Furthermore,	SVR	may	fore‐
stall	 the	progression	of	 liver	diseases	with	subsequent	reduction	
in	liver‐related	complications	including	HCC,	hepatic	decompensa‐
tion,	and	both	liver	related	as	well	as	all‐cause	mortality.
HCV	genotype	1	(GT1)	is	the	most	prevalent	recurrence	affecting	
the	majority	of	patients	post	LT.10,11	However,	the	effectiveness	and	tol‐
erability	of	various	of	combinations	of	DAAs	on	specific	genotype	of	
HCV	recurrence	in	LT	recipients	remain	largely	unknown.12	In	this	study,	
we	performed	a	systematic	review	and	meta‐analysis	in	order	to	provide	
a	comprehensive,	reliable,	and	up‐to‐date	assessment	of	DAA	treatment	
for	GT1	HCV	recurrence	post	transplantation.	Our	results	may	provide	
additional guidance for clinical practice and future research.
2  | MATERIALS AND METHODS
2.1 | Literature search
We have conducted a systematic search of various electronic data‐
bases,	including	Ovid	Medline,	EMBASE,	Web	of	Science,	Cochrane	
Database,	 and	 Google	 Scholar	 for	 relevant	 studies	 published	 from	
inception	until	 July,	2018.	The	search	was	designed	and	conducted	
by	 an	 experienced	 medical	 librarian	 with	 input	 from	 the	 study	 in‐
vestigators,	 using	 controlled	 vocabulary	 supplemented	 with	 key‐
words	 (“sofosbuvir”	 OR	 “ribavirin”	 OR	 “ritonavir”	 OR	 “asunaprevir”	
OR	 “simeprevir”	 OR	 “daclatasvir”	 OR	 “ombitasvir”	 OR	 “ledipasvir”	
OR	 “velpatasvir”	OR	 “grazoprevir”	OR	 “elbasvir”	OR	 “DAA”	OR	 “di‐
rect‐acting	antivirals”	AND	“liver	transplantation”	AND	“hepatitis	C”	
OR	 “HCV”	 AND	 “Genotype	 1”	 OR	 “GT1”)	 (Supporting	 Information	
method	S1).	In	addition,	the	bibliographies	of	relevant	review	articles	
and all included studies were manually reviewed to identify relevant 
studies.	No	restrictions	were	applied	to	language	due	to	the	limited	
number	of	manuscripts.	Abstracts	from	conferences	were	excluded	in	
our	database	search.	Besides,	the	reference	lists	of	included	articles	
and relevant systematic reviews were manually searched.
2.2 | Inclusion and exclusion criteria
All	records	identified	through	database	searches	were	downloaded	
and duplicate records were removed. The title and abstract of re‐
maining records were screened for relevance to liver disease and 
human	subjects.	After	this	initial	screening,	the	lists	of	selected	stud‐
ies	were	cross‐checked	to	resolve	discrepancies.	Subsequently,	full	
articles were retrieved for detailed assessment.
Reports were included if they were original studies which con‐
tained	at	 least	 five	patients,	presented	effectiveness	of	 treatment	
of	second	generation	of	 interferon‐free	DAA	regimens	for	at	 least	
12	weeks	 in	 adult	 LT	 recipients	with	GT1	HCV	 recurrence.	 In	 ad‐
dition,	these	 included	studies	should	present	proportion	of	SVR12	
after	 the	end	of	 the	treatment.	We	excluded	studies	 that	enrolled	
LT	recipients	featured	coinfection	with	hepatitis	A,	B,	D,	E	virus	or	
human	 immunodeficiency	virus	 (HIV).	Besides,	 studies	without	 re‐
porting	AEs	and/or	sAEs	were	also	excluded.
2.3 | Study selection and data extraction
Two	 reviewers	 (JL	 and	 BM)	 worked	 independently	 to	 determine	
whether	 a	 study	 met	 inclusion	 criteria,	 abstracted	 information	 to	
assess	the	methodological	validity	of	each	candidate	study,	and	ex‐
tracted data with structured data collection forms. The reviewers 
resolved	discrepancies	by	jointly	reviewing	the	study	in	question.	If	
no	consensus	was	reached,	a	third	reviewer	(QP),	unaware	of	prior	
determinations,	functioned	as	an	arbiter.
Extracted	information	for	this	study	include	study	design,	immu‐
nosuppression	protocols,	dosage	adjust,	DAA	combinations,	collab‐
oration	 (single	or	multicenter)	 and	patient	 demographics	 including	
age,	gender,	ethnicity,	viral	load,	degree	of	fibrosis.	We	also	obtained	
data	of	treatment	outcomes	of	SVR12.	 In	addition,	data	about	the	
tolerability	of	DAA	treatment	were	also	collected.
2.4 | Quality assessment
The	quality	of	 included	studies	was	 rated	using	 the	 institute	of	
Health	Economics	(IHE)	quality	appraisal	checklist,	which	is	usu‐
ally	 employed	 for	 assessment	 of	 the	 quality	 of	 case	 series.	 As	
all	 of	 the	 included	 studies	 were	 single‐arm	 reports,	 an	 assess‐
ment	 tool	 for	 case	 series	 is	 more	 suitable	 than	 the	 Newcastle	
Ottawa	Scale	 (NOS).	 In	 this	20‐item	checklist,	 both	 risk	of	bias	
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and	 quality	 of	 reporting	were	 scored	 by	 yes,	 no,	 or	 partial/un‐
clear	 answers.	 Eight	 quality	 parameters	 including	 study	 objec‐
tive	(0‐1	points),	study	design	(0‐3	points),	study	population	(0‐3	
points),	 intervention	 and	 co‐intervention	 (0‐2	 points),	 outcome	
measure	(0‐4	points),	statistical	analysis	(0‐1	points),	results	and	
conclusions	(0‐5	points),	and	competing	interests	and	sources	of	
support	(0‐1	points)	were	used	to	assess	included	studies.	In	our	
analysis,	 studies	with	0‐2,	3‐5,	6‐8,	and	≥9	points	were	consid‐
ered	 as	 having	 low,	moderate,	 high,	 and	 very	 high	 risk	 of	 bias,	
respectively. Quality assessment was done by two independent 
authors	(JL	and	BM),	and	disagreements	were	solved	by	the	third	
author	(QP).
2.5 | Statistical analysis
After	checking	for	consistency,	 the	Metaprop	module	 in	 the	R‐3.4.2	
statistical	 software	 package	 was	 used	 for	 the	 meta‐analysis.	 Given	
that,	the	SVR12	proportion	in	many	articles	are	close	to	100%.	So	the	
F I G U R E  1  Flow	chart	for	the	systematic	review	and	meta‐analysis	of	the	literature
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proportion	of	SVR12	reported	in	each	study	was	Free‐Turkey	double	
arcsine	transformed	prior	to	compute	the	pooled	estimate	rate.	A	95%	
confidence	interval	(CI)	was	estimated	using	Wilson	score	method.	We	
performed	meta‐analysis	of	proportion	 to	compute	 the	pooled	esti‐
mate	proportions	using	a	 random	effects	model	 (DerSimonian‐Laird	
Method).	 Heterogeneity	 across	 the	 included	 studies	 was	 assessed	
using	 the	 Cochran	 Q‐statistics	 and	 I2	 statistics,	 with	 I2 statistics 
25%‐50%,	50%‐75%,	and	>75%	considered	as	mild,	moderate,	and	se‐
vere	heterogeneity,	respectively.	Based	on	the	available	data,	subgroup	
meta‐analysis	were	performed	using	the	Q test to determine whether 
the	pooled	estimate	proportion	of	SVR12	varied	by	study	type	(retro‐
spective	study	or	perspective	study),	with	or	without	Ribavirin	(RBV),	
METAVIR	score	(F0‐F2	or	F3‐F4),	and	different	kinds	of	regimens	SOF/
SMV	with	or	without	RBV,	SOF/Ledipasvir	(LDV),	Asunaprevir	(ASV)/
SMV,	Daclatasvir	(DCV)/SMV	with	or	without	RBV	and	Paritaprevir/
Ritonavir/Ombitasivir/Dasabuvir	 (PrOD).	 Funnel	 plots	 and	 Egger	 re‐
gression test were used to assess potential publication biases.
Ethical	 approval	 or	 inform	 consent	 from	 patients	 was	 not	 re‐
quired,	 because	 our	 data	 were	 extracted	 from	 previous	 studies.	
Nevertheless,	the	included	studies	in	our	review	did	obtain	patient	
consent and each study was approved by ethics committee.
3  | RESULTS
3.1 | Literature search
Our	 search	 strategy	 identified	 2747	 articles	 for	 inclusion.	 After	
removing	 duplicate	 studies,	 2655	 studies	 were	 further	 evaluated	
for	 eligibility.	 Of	 these,	 1593	 studies	 were	 excluded,	 which	 had	
no	DAA,	HCV	GT1,	 or	 LT‐related	 items.	After	 screening	 the	 titles	
and	abstracts,	 another	950	 studies	were	excluded;	744	 studies	of	
them	 included	 ineligible	study	participants,	206	with	small	 sample	
size.	Finally,	112	studies	were	 retrieved	and	evaluated	 in	 full	 text.	
Of	those	reviewed	in	detail,	96	studies	were	excluded	due	to	dupli‐
cate	publication,	improper	study	design,	or	incomplete	information	
of	 effectiveness	 and	 tolerability.	 Eventually,	 16	 studies,	 published	
until	July	2018,	involving	885	patients	were	eligible	for	the	qualita‐
tive	and	quantitative	synthesis	as	detailed	in	Figure	1.	Based	on	the	
Institute	of	Health	Economics	 (IHE)	 quality	 appraisal	 checklist,	 six	
studies	were	of	low	risk	of	bias	compared	to	10	studies	with	moder‐
ate	risk	of	bias.	To	date,	no	randomized	controlled	trial	has	been	pub‐
lished	exploring	the	efficacy	and	tolerability	of	DAAs	on	recurrence	
of	post	LT.	The	16	included	studies	were	performed	by	five	different	
countries.	Among	them,	62.5%	were	conducted	in	USA,	18.75%	in	
Japan,	6.25%	in	UK,	6.25%	in	Germany,	and	6.25%	in	Spain.	Ten	of	
the	 included	studies	were	multicenter	studies	and	six	were	single‐
center	studies.	All	of	these	studies	were	published	in	full	text.
3.2 | Baseline characteristics
Tables	1	and	2	summarize	the	baseline	patient	demographic	and	clin‐
ical	characteristics.	Except	one	study13 that did not report patient 
ethnicity,	the	majority	of	patients	were	Caucasian,	male,	with	a	mean	
age	of	approximately	60‐year‐old,	had	GT1a	HCV	 recurrence,	 and	
received tacrolimus as part of their immunosuppressive treatment. 
Five	 different	 DAA	 combination	 protocols	 were	 described:	 SOF/
SMV	with	 or	without	 RBV	 (n	=	8)13‐20;	 SOF/LDV	 (n	=	3)21‐23;	 ASV/
SMV	(n	=	2)24,25;	DCV/SMV	with	or	without	RBV	(n	=	2)26,27;	PrOD	
(n	=	1).28	 Detailed	 baseline	 characteristics	 of	 the	 included	 studies	
are provided in Tables 1 and 2.
TA B L E  1  Baseline	characteristics	of	studies	included
Author Year Cases Study design Ethnicity (C/B/A/H/O)
Genotype 
1a (%) Male (%) Age(Years) Collaboration
Jacqueline 2016 46 Prospective 37/8/1/0/0 33	(71.7%) 34	(73.9%) 60	(49‐68) Multiple‐center‐
Robert 2016 151 Prospective 118/14/0/0/19 87	(57.6%) 112	(74.2%) 61	(46‐78) Multiple‐center
Lutchman 2016 50 Retrospective 25/0/0/16/9 32	(64.0%) 42	(84.0%0 61.3	±	7.1 Single‐center
Suraki 2015 123 Retrospective 91/12/0/12/8 74	(60.2%) 93	(75.6%) 61	±	6 Multiple‐center
Saro 2015 32 Retrospective 11/0/2/19/0 22	(68.8%) 21	(65.6%) 58	(47‐71) Single‐center
Jackson 2016 67 Retrospective ‐ 23	(34.3%) 46	(68.7%) 61.5	±	6.6 Multiple‐center
Punzalan 2015 42 Retrospective 34/1/1/6/0 33	(78.6%) 28	(66.7%) 58 Single‐center
Toru 2017 74 Retrospective 0/0/74/0/0 ‐ 32	(43.2%) 62.7	±	4.5 Multiple‐center
Kerstin 2015 6 Retrospective 6/0/0/0/0 5	(83.3%) 5	(83.3%) 58.5	(50‐63) Single‐center
Masaki 2017 9 Retrospective 0/0/9/0/0 ‐ 5	(55.6%) 64.7	±	0.85 Single‐center
Neil 2015 56 Retrospective 48/0/0/0/8 44	(78.6%) 42	(75.0%) 61 Multiple‐center
Paul 2014 34 Prospective 29/4/0/0/1 29	(85.3%) 27	(79.4%) 59.6	±	6.6 Multiple‐center
Yoshihide 2017 54 Retrospective 0/0/54/0/0 ‐ 25	(46.3%) 64	(47‐77) Multiple‐center
Mohamed 2017 60 Retrospective 53/0/0/0/7 47	(78.3%) 42	(70.0%) 59.9	±	7.25 Single‐center
Mohamed	A 2016 46 Retrospective 32/0/0/0/14 26	(56.5%) 32	(69.6%) 62.0	±	8 Multiple‐center
Xavier 2016 35 Prospective 34/0/0/0/1 ‐ 22	(62.9%) 62	(27‐69) Multiple‐center
A,	Asian;	B,	black;	C,	Causian;	H,	Hispanic;	O,	others.
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3.3 | Outcomes
3.3.1 | The efficacy and tolerability of 
DAA treatment
Once	 DAA	 treatment	 completed,	 patients	 were	 followed	 up	 for	
evaluating	SVR12	proportion.	 In	 total,	805	out	of	885	 (91.0%)	pa‐
tients	 successfully	 achieved	 SVR12.	 The	 pooled	 estimate	 SVR12	
proportion	among	all	 LT	 recipients	were	93%	 (95%	CI:	0.89,	0.96),	
with moderate heterogeneity observed in a random effects model 
(τ2=0.01,	P	<	0.001,	I2=75%,	Figure	2).	The	expected	shape	observed	
in	the	funnel	plots	and	results	of	the	Egger's	test	(P	=	0.44)	indicated	
no	significant	publication	bias	(Figure	S1	and	S2).	AEs	commonly	oc‐
curred	in	these	patients.	General	symptoms	including	fever,	fatigue,	
and	dizziness	were	the	most	common	AEs	with	pooled	estimate	rate	
of	 37%	 (95%	CI:	 0.14,	 0.64;	 τ2	=	0.30,	P	<	0.01,	 I2	=	98%,	 Random	
effects	 model,	 Figure	 S3).	 Pooled	 estimate	 incidence	 rate	 of	 gas‐
trointestinal	AEs	was	10%	 (95%	CI:	 0.02,	0.23;	 τ2	=	0.11,	P	<	0.01,	
I2	=	96%,	Random	effects	model,	Figure	S4)	and	pooled	estimate	in‐
cidence	rate	of	skin	problems	was	7%	(95%	CI:	0.02,	0.15;	τ2	=	0.06,	
TA B L E  2  Baseline	characteristics	of	studies	Included
Author
Immunosuppressive 
protocols Dosage adjust
Viral Load 
Log IU/mL DAAs protocol
Duration of DAA 
treatment
Duration 
from LT (M)
Jacqueline TAC	89%,	MMF	41%,	
SIR	11%
15	pts	underwent	
dosage adjust
5.8 SOF+SMV	±RBV 12/24	wk 54	(9‐171)
Robert s. TAC	80%,	CsA	10%,	
both	0.6%;	MMF/MPA	
40%
NR ‐ SOF+SMV±RBV 12	wk 60	(0‐276)
Lutchman 96%	TAC 1 pts changed 
cyclosporin	into	TAC
6.3	±	1.2 SOF+SMV 12	wk ‐
Suraki TAC	91%,CsA	8% NR ‐ SOF+SMV+RBV 12	wk 57	±	65
Saro TAC	66%,	CsA	3%,	RAP	
3%,	TAC+MMF	25%,	
CsA+MMF	3%
NR 6.58 SOF+SMV 12	wk 48	(7‐166)
Jackson TAC	84%,	CsA	6%,	SIR	
6%
NR ‐ SOF+SMV 12	wk ‐
Punzalan TAC	88%,CsA	7%,RAP	
5%
7	pts	TAC	dosage	
decreased
‐ SOF+SMV 12	wk ‐
Toru TAC	45%,	TAC+MMF	
45%,	TAC+MMF+STE	
45%,	MMF	4%,	CsA	
1%
NR 6.3 ASV+DCV 24	wk ‐
Kerstin ‐ No	change 6.06 DCV+SMV 24	wk 15	(6‐162)
Masaki TAC	56%+MMF,	MMF	
22%,	TAC	11%,	
CsA+PRED	11%
NR 6.11 ASV+DCV 24	wk 70	(3‐121)
Neil CsA	9%,	TAC	71%,	
MPA	2%,	SIR	18%
8pts	TAC	dosage	
increased,	9	pts	
decreased;	2pts	CsA	
dosage decreased; 3 
pts	SIR	dosage	
increased,	3pts	
decreased
‐ SOF+SMV±RBV 12	wk 53
Paul TAC	85%,	CsA	15%,	
MMF	32%,	PRED	6%
No	change 6.6 PrOD 12	wk ‐
Yoshihide TAC	75%,	MMF	46%,	
PRED	28%
NR 6.5 LDV+SOF 12	wk 61	(1‐158)
Mohamed ‐ NR ‐ LDV+SOF 12	wk 42	(11‐113)
Mohamed	A TAC	76%,	SIR	13%,	CsA	
9%,	EVR	2%,	MMF	
33%
Minimal	changed	but	
details not report
7.79 LDV+SOF 12/24	wk 30	(2‐117)
Xavier	2016 TAC	71%,	CsA	29% NR 6.9 SMV+DCV+RBV 24	wk 47	(14‐114)
ASV,	 Asunaprevir;	 CsA,	 Cyclosporine	 A;	 DAAs,	 direct‐acting	 antivirals;	 DCV,	 Daclatavir;	 EVR,	 Everolimus;	 LDV,	 Ledipasvir;	 m,	 months;	 MMF,	
Mycophenolate	 Mofetil;	 MPA,	 Mycophenolic	 Acid;	 PrOD,	 Paritaprevir/Ritonavir/Ombitasivir/Dasabuvir;	 Pts,	 patients;	 PRED,	 Prednisone;	 RAP,	
Rapamune;	RBV,	Ribavirin;	SIR,	Sirolimus;	STE,	Steroid;	SOF,	Sofosbuvir;	SMV,	Simeprevir;	TAC,	Tacrolimus.
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P	<	0.01,	 I2	=	93%,	 Random	 effects	 model,	 Figure	 S5).	 SAEs	 were	
mainly	associated	with	kidney	injury,	were	reported	in	45	patients,	
and	 12	 patients	 died	 during	 the	 treatment	 period	 (Table	 3).	 The	
pooled	estimate	rate	of	sAEs	was	4%	(95%	CI:	0.01,	0.07,	τ2	=	0.02,	
P	<	0.01,	I2	=	81%,	Random	effects	model,	Figure	3).
3.3.2 | Study design
Twelve retrospective and four prospective studies were included. 
There	was	no	significant	difference	in	pooled	estimate	SVR12	pro‐
portion	when	comparing	studies	of	prospective,	91%	(95%	CI:	0.87,	
0.95),	versus	retrospective,	93%	(95%	CI:	0.88,	0.97)	(P	=	0.44,	Figure	
S6,	Random	effects	model).
3.3.3 | Degree of liver fibrosis
The	METAVIR	 Fibrosis	 Score,	 simply	 put,	 is	 a	 evaluate	 system	 to	
determine the level of liver fibrosis.29	The	METAVIR	Fibrosis	Score	
grades	the	degree	of	fibrosis	on	a	5‐point	scale	from	0	to	4.	Fibrosis	
scores	range	from	F0	to	F4	 (F0	stage,	no	fibrosis;	F1	stage,	portal	
fibrosis	without	septa;	F2	stage,	portal	fibrosis	with	septa;	F3	stage,	
numerous	 septa	 without	 cirrhosis;	 F4	 stage,	 cirrhosis).	 A	 total	 of	
eight studies evaluated the levels of fibrosis and cirrhosis of pa‐
tients	according	to	METAVIR	Fibrosis	Score.	The	pooled	SVR12	rate	
estimates	among	patients	with	METAVIR	Fibrosis	Score	 for	F0‐F2	
stages	were	 97%	 (95%	 CI:	 0.93,	 0.99)	 compared	 to	 85%	 (95%	 CI:	
0.79,	0.90)	for	stages	F3‐F4.	There	was	a	trend	for	a	higher	SVR12	
rate	in	patients	with	F0‐F2	stages	than	patients	with	F3‐F4	stages	
(P	<	0.01,	Figure	4,	Random	effects	model).
3.3.4 | Different combination of DAA regimens
Sixteen	studies	which	contained	five	different	DAA	regimens	were	
administered	into	clinical	treatment	of	LT	recipients	with	recurrent	
GT1	HCV	 infection.	 The	 pooled	 estimate	 SVR12	proportion	were	
97%	(95	CI:	0.89,	1.00),	81%	(95%	CI:	0.72,	0.89),	100%	(95%	CI:	0.98,	
1.00),	90%	(95%	CI:	0.80,	0.97),	and	90%	(95%	CI:	0.87,	0.92)	among	
patients	who	underwent	treatment	of	PrOD,	ASV/DCV,	LDV/SOF,	
TA B L E  3   Incidence	of	adverse	events	and	serious	adverse	events	during	direct‐acting	antivirals	treatment	for	patients	of	hepatitis	C	virus	 
genotype 1 recurrence post liver transplantation
Jacqueline 
2016 Robert 2016 Lutchman 2016 Suraki 2015 Saro 2015 Jackson 2016
Punzalan  
2015 Toru 2017 Kerstin 2015 Masaki 2017 Neil 2015 Paul 2014 Yoshihide 2017
Mohamed 
2017
Mohamed 
A.2016
Xavier 
2016
GI	Symptoms
Nausea 23.9% 11.3% 4.4% 5.0% 3.0% 11.3% 36.0% 24.0% 3.0%
Diarrhea 21.7% 26.0% 2.0% 14.0%
Vomitting 17.4%
Constipation 10.9%
De‐or	increased	
appetite
13.0% 4.4% 3.0% 30.0% 21.0%
General Symptoms
Perspiration 17.0%
Cough 32.0% 14.0%
Insomnia 13.0% 35.9% 2.0% 21.0% 26.0% 5.0%
Dizziness 9.0% 7.0% 18.0%
Fever 3.0%
Headache 37.0% 18.5% 8.7% 5.0% 25.0% 18.5% 36.0% 44.0% 23.0% 5.0% 14.0%
Fatigue 34.8% 25.2% 44.6% 13.0% 22.0% 25.2% 2.4% 50.0% 71.0% 50.0% 20.0% 6.0% 9.0%
Skin	Problems
Photosensitivity,	
pruritus,	rash
21.7% 13.9% 44.6% 6.0% 6.0% 13.9% 12.0% 35.0% 21.0% 31.0%
Anemia 10.6% 77.0% 10.6% 30.0% 29.0% 54.0%
Dysnoea 28.2% 4.0% 11.0%
Infection	and	
infestation
14.6% 14.6% 2.0%
Joint or muscle 
pain
4.4% 9.0% 2.4% 7.0% 39.0%
Others 11.9% 14.0% 21.5% 20.2% 22.2% 28.0% 42.0% 10.0%
sAEs 10.9% 11.9% 6.5% 2.4% 0 11.9% 2.4% 0 0 0 3.6% 6.0% 13.0% 0 0 23.0%
GI,	gastrointestinal;	sAEs,	serious	adverse	events.
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SMV/DCV	with	or	without	RBV	and	SMV/SOF	with	or	without	RBV,	
respectively	(Figure	S7,	Random	effects	model).
3.3.5 | With or without RBV
A	total	of	124	LT	recipients	used	RBV	as	combinational	 treatment	
compared	 to	 761	 recipients	without.	 The	 pooled	 estimate	 SVR12	
proportion	of	 recipients	 treated	with	RBV	was	90%	 (95%CI:	0.84,	
0.94).	 For	 recipients	 treated	 without	 RBV,	 the	 pooled	 proportion	
was	94%	(95%CI:	0.89,	0.97).	There	was	no	significant	difference	in	
SVR12	 proportion	 between	 LT	 recipients	 treated	with	 or	without	
RBV	(P	=	0.23,	Figure	S8,	Random	effects	model).
4  | DISCUSSION
The	current	systematic	review	and	meta‐analysis	included	16	studies	
comprising	885	patients	to	assess	the	outcome	of	DAA	treatment	for	
liver	transplant	recipients	with	recurrent	GT1	HCV	infection.	Overall,	
the	pooled	SVR12	and	sAEs	proportion	were	93%	and	4%,	representing	
a rather good outcome. Subgroup analyses revealed clear difference in 
SVR12	rates	for	different	treatment	strategies.	The	pooled	estimate	
proportion	for	combination	of	LDV/SOF	appears	much	higher	than	the	
other	four	combinations.	In	addition,	the	efficacy	of	DAA	treatment	is	
closely	associated	with	fibrosis	or	cirrhosis	levels,	which	highlights	the	
necessity	of	early	initiation	of	DAA	treatment	in	these	patients.
The	 pooled	 estimate	 results	 of	 SVR12	 provided	 evidence	 that	
DAA	treatment	was	clinically	effective	in	eradicating	GT1	HCV	re‐
currence	post	LT.	This	is	comparable	to	the	pooled	estimate	results	
from	a	recent	meta‐analysis	that	contained	all	HCV	GTs.30	Of	note,	
the	 unbalanced	 application	 of	DAAs	 for	GT1	HCV	 recurrence	 ex‐
ists	among	different	regions.	There	is	a	trend	that	the	first‐class	of	
DAAs	 are	 commonly	 used	 in	 European	 or	 North	 American	 coun‐
tries.	For	many	countries,	even	like	Japan,	cost‐effectiveness	other	
than	SVR	rate	is	the	first	consideration	for	clinicians.24,25	However,	
in	Asia‐pacific	or	Africa	countries,	HCV	has	distinct	epidemiology.	
Furthermore,	DAA	 availability	 has	 been	 delayed	 due	 to	 economic	
constraints and regulatory rules.31	Although	two	studies	from	Japan	
TA B L E  3   Incidence	of	adverse	events	and	serious	adverse	events	during	direct‐acting	antivirals	treatment	for	patients	of	hepatitis	C	virus	 
genotype 1 recurrence post liver transplantation
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2016
GI	Symptoms
Nausea 23.9% 11.3% 4.4% 5.0% 3.0% 11.3% 36.0% 24.0% 3.0%
Diarrhea 21.7% 26.0% 2.0% 14.0%
Vomitting 17.4%
Constipation 10.9%
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Dizziness 9.0% 7.0% 18.0%
Fever 3.0%
Headache 37.0% 18.5% 8.7% 5.0% 25.0% 18.5% 36.0% 44.0% 23.0% 5.0% 14.0%
Fatigue 34.8% 25.2% 44.6% 13.0% 22.0% 25.2% 2.4% 50.0% 71.0% 50.0% 20.0% 6.0% 9.0%
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21.7% 13.9% 44.6% 6.0% 6.0% 13.9% 12.0% 35.0% 21.0% 31.0%
Anemia 10.6% 77.0% 10.6% 30.0% 29.0% 54.0%
Dysnoea 28.2% 4.0% 11.0%
Infection	and	
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Joint or muscle 
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4.4% 9.0% 2.4% 7.0% 39.0%
Others 11.9% 14.0% 21.5% 20.2% 22.2% 28.0% 42.0% 10.0%
sAEs 10.9% 11.9% 6.5% 2.4% 0 11.9% 2.4% 0 0 0 3.6% 6.0% 13.0% 0 0 23.0%
GI,	gastrointestinal;	sAEs,	serious	adverse	events.
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suggested	that	DAA	treatment	is	effective	in	Asian	patients,	multire‐
gional and systematic studies should be combined to further confirm 
the	effectiveness	of	DAA	treatment	for	different	regions.
The	 average	 time	 of	 progression	 from	 initial	HCV	 infection	 to	
cirrhosis	 is	about	30	years,	but	20%‐30%	of	 liver	transplant	recipi‐
ents	develop	cirrhosis	within	5	years.32 Retransplantation is the only 
F I G U R E  2  Pooled	estimate	proportion	of	12	weeks	sustained	virologic	response	after	treatment	completion	and	95%	confidence	interval	
after	direct‐acting	antivirals	treatment	of	GT1	HCV	recurrence	post	liver	transplantation	from	16	studies.	Abbreviations:	CI,	confidence	
interval;	Events,	the	number	of	patients	who	reached	SVR12;	Total,	the	number	of	patients	analyzed
F I G U R E  3  Pooled	estimate	proportion	of	serious	adverse	events	and	95%	confidence	interval	after	direct‐acting	antivirals	of	GT1	HCV	
recurrence	post	liver	transplantation	from	16	studies.	Abbreviations:	CI,	confidence	interval;	Events,	the	number	of	patients	who	reached	
SVR12;	Total,	the	number	of	patients	analyzed
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option	 to	 achieve	 long‐term	 survival	 of	 patients	 with	 decompen‐
sated	 cirrhosis.	However,	 due	 to	 organ	 shortage	 and	 poor	 clinical	
outcome,	 retransplantation	 is	 clearly	 not	 a	 sustainable	 solution.33 
In	our	 subgroup	analysis	of	 liver	 transplant	 recipients	with	SVR12	
rate	and	fibrosis	data	(METAVIR	Fibrosis	Score),	our	detailed	analysis	
supports	 the	 latest	evidence‐based	guidelines	 that	DAAs	also	 can	
be	 effectively	 used	 in	 eradicating	HCV	 in	 patients	with	 advanced	
fibrosis	or	cirrhosis	post	LT.34	We	observed	a	higher	SVR12	pooled	
estimate proportion in patients with mild fibrosis compared with 
those	of	advanced	fibrosis	or	cirrhosis,	with	a	trend	favoring	SVR12	
in	patients	with	mild	fibrosis.	Our	results	indicated	that	the	capabil‐
ity	of	HCV	eradication	by	DAAs	may	be	correlated	with	the	levels	of	
liver	fibrosis	or	cirrhosis.	Therefore,	DAA	treatment	is	recommended	
to be initiated early after transplantation.
Five	different	combinations	of	DAA	treatment	were	identified	in	
our	 systematic	 review	and	meta‐analysis.	There	are	 important	dif‐
ferences	among	the	strategies,	such	as	addition	of	RBV,	duration	of	
treatment,	and	potential	drug	interactions.	Among	these	regimens,	
SMV/SOF	with	or	without	RBV	were	most	commonly	used	with	a	
pooled	 estimate	 SVR12	 proportion	 of	 90%,	 which	 is	 comparable	
with	 a	 recent	 study	 reporting	 SVR12	 rate	 of	 88%.30	 A	 number	 of	
studies	have	pointed	out	that	SMV	may	interact	with	Cyclosporine	
A	(CsA),	and	therefore	the	immunosuppressant	tacrolimus	is	recom‐
mended to be used.35	In	general,	the	combination	of	SMV	and	SOF	
with	or	without	RBV	seems	to	be	a	safe	regimen	even	at	the	early	
stage	of	post	 transplantation,	when	constant	changes	of	 immuno‐
suppressive	medication	are	often	required	and	the	patients	are	vul‐
nerable	to	side	effects.	The	combination	of	LDV	and	SOF	has	been	
used	in	three	studies.	The	safety	and	efficacy	of	combination	of	LDV	
and	SOF	was	firstly	confirmed	 in	a	US‐based	SOLAR‐2	study	with	
a	 SVR12	 rate	 of	 96%	 and	 SVR24	 rate	 of	 98%.36 The pooled esti‐
mate	SVR12	proportion	of	LDV	and	SOF	from	our	study	is	as	high	as	
100%.	Only	one	study	reported	their	results	for	the	DAA	combina‐
tion	regimen	of	PrOD	in	GT1	HCV	recurrence	post	LT	with	SVR12	
proportion	 of	 97%.	Unfortunately,	 PrOD	 is	 contraindicated	 in	 pa‐
tients	with	cirrhosis	and	has	a	potential	to	increase	the	plasma	CsA	
levels	by	five	to	six	folds	and	tacrolimus	levels	by	60‐85	folds,	which	
limited its clinical application.28	In	addition,	efficacy	and	safety	were	
not	established	for	shorter	duration	therapy,	or	more	advanced	fi‐
brosis/cirrhosis	in	a	real	world	setting.	Combination	of	ASV	and	DCV	
F I G U R E  4  Comparison	of	pooled	estimate	proportion	of	12	weeks	sustained	virologic	response	after	treatment	completion	and	95%	
confidence	interval	between	METAVIR	Fibrosis	Stages	F0‐F2	and	F3‐F4	after	direct‐acting	antivirals	treatment	of	hepatitis	C	virus	genotype	
1	recurrence	post	liver	transplantation.	Abbreviations:	CI,	confidence	interval;	Events,	the	number	of	patients	who	reached	SVR12;	Total,	
the	number	of	patients	analyzed
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were administered by two Japanese studies with the lowest pooled 
estimate	SVR12	proportion	of	81%.	Although	this	combination	had	a	
cost‐effective	advantage,	increased	transaminase	levels	were	com‐
monly	associated	with	ASV.37,38 Two studies have reported a pooled 
estimate	SVR12	proportion	of	90%	with	DAA	combination	of	SMV/
DCV	with	or	without	RBV.	Although	the	pooled	estimate	SVR12	pro‐
portion	was	satisfactory,	two	limitations	including	small	sample	size	
and	prolonged	 treatment	period	of	24	weeks	 in	 these	 two	studies	
should be noted.
There	 is	 ongoing	 debate	 whether	 adding	 RBV	 to	 interferon‐
free	treatment	strategy	 is	necessary	for	treating	HCV	recurrence	
after	LT.16	RBV	has	been	used	for	over	40	years	in	combination	for	
treating	HCV	with	an	obscure	understanding	of	its	mechanism‐of‐
action.39,40	What	 is	 clear,	 however,	 is	 adverse	 effects.	Hemolytic	
anemia has been observed in about one third of the patients. 
Lymphopenias,	pruritus,	and	rash	also	commonly	occur.	Thus,	pa‐
tients	 treated	with	RBV	often	 need	 a	 close	monitoring	 and	dose	
adjustment,	especially	for	those	with	chronic	kidney	disease.	 It	 is	
also	recommended	that	patients	treated	with	RBV	should	undergo	
at	 least	6‐month	washout	period	due	 to	 the	possible	 teratogenic	
and embryocidal effects.40‐42	In	current	study,	we	observed	an	in‐
creased	pooled	estimate	incidence	rate	of	sAEs	in	patients	treated	
with	 RBV,	 in	 accordance	 with	 the	 results	 from	 previous	 studies.	
Given	 that	 a	 number	 of	 studies	 have	 pointed	 out	 RBV	were	 not	
correlated	with	an	increased	SVR12	rate,13,16,20,43 we compared pa‐
tients	treated	or	not	treated	with	this	medication.	Our	results	also	
indicated	 that	 RBV	was	 not	 correlated	with	 an	 increased	 pooled	
estimate	 SVR12	 proportion.	We	 also	 assessed	 the	 tolerability	 of	
DAA	 treatment	 by	 analyzing	 pooled	 estimate	 proportion	 of	 AEs	
and	sAEs.	General	symptoms,	gastrointestinal	symptoms,	and	skin	
complaints were presented with a pooled estimate incidence rate 
of	37%,	10%	and	7%,	respectively.	SAEs	including	death	caused	by	
hepatic	or	renal	failure,	pneumonia,	bone	marrow	failure,	acute	kid‐
ney,	liver	or	other	major	organ	infection,	hepatic	decompensation,	
spontaneous	bacterial	peritonitis,	and	sepsis,	were	analyzed	with	a	
pooled	estimate	incidence	rate	of	4%	(I2	=	81%).
Among	them,	renal	dysfunction	was	reported	in	45	patients,	
and	12	patients	died	during	the	treatment	period.	Impaired	renal	
function commonly occurred in liver transplant recipients with 
the	prevalence	ranging	from	17%	to	95%.44,45	Approximately	40%	
of	 these	 patients	 had	 already	 experienced	 a	 hepatorenal	 syn‐
drome pretransplantation.46	In	addition,	toxic	reasons,	ischemia	
reperfusion	and	Calcineurin	Inhibitor	(CNI)‐associated	nephrop‐
athy were account for renal dysfunction post transplantation.47 
Although	the	exact	pathophysiological	mechanisms	are	not	fully	
understood,	HCV	infection	may	influence	renal	function	through	
different pathways.48	A	recent	study	documented	that	those	pa‐
tients	with	HCV	recurrence	after	LT	will	absolutely	benefit	from	
HCV	elimination	but	will	be	at	a	higher	risk	for	renal	dysfunction	
or	failure	associated	with	antiviral	drugs	like	SOF.49	Unlike	most	
DAAs,	the	nucleotide	analogue	NS5B	polymerase	inhibitor	SOF	
was	renally	excreted.	For	area	under	the	curves	(AUCs)	of	SOF,	
patients	with	end‐stage	renal	diseases	was	45‐fold	and	35‐fold	
higher compared to normal renal function when dosed 1 hour 
before	 or	 1	hour	 after	 hemodialysis,	 respectively.50	 However,	
there	are	conflicting	data	about	the	application	of	SOF	in	clinical	
treatment.	 Saxena	et	 al	 51 evaluated the safety and efficacy of 
SOF‐based	therapy	in	HCV‐infected	patients	with	impaired	renal	
function.	High‐SVR	rate	of	83%	was	achieved	with	high	rate	of	
renal	dysfunction	and	sAEs	observed.	A	prospective	multicenter	
cohort	 study	 enrolled	 50	 patients	 with	 Glomerular	 Filtration	
Rate	 (GFR)	<35	mL/min	per	1.73	m2	 for	 treatment	with	 a	 SOF‐
based	therapy.	All	genotypes	were	included	and	more	than	half	
of them were cirrhotic patients. The results indicated that there 
is	 no	 significant	 change	 in	 GFR	 for	 patients	 who	 were	 not	 on	
dialysis.52	More	recently,	Teegen	et	al	49 also documented that a 
dose	reduction	for	SOF	did	not	seem	to	be	necessary	to	prevent	
further	 renal	 damage.	 Thus,	 additional	 data	 are	 still	 needed	 to	
further	assess	the	safety	of	SOF	in	transplant	recipients.
CNIs	are	the	backbone	of	 immunosuppressive	treatment	of	LT.	
Eighty	percent	of	 liver	 transplant	 recipients	were	using	 tacrolimus	
alone or in combination with mycophenolate 1 year post transplan‐
tation.53	Although	CNIs	can	reduce	the	incidence	of	acute	injection	
and	 improve	 overall	 survival,	 they	 are	 inevitably	 associated	 with	
nephrotoxicity	which	 is	 reflected	 in	 tubular	 atrophy,	 interstitial	 fi‐
brosis,	and	glomerulosclerosis	on	kidney	biopsy.54	However,	so	far,	
the	use	of	a	CNI‐free	regimen	is	still	challenging	and	the	trend	in	LT	
was	to	use	regimens	that	minimize	the	use	of	CNIs	 in	combination	
with	mycophenolate	mofetil	 (MMF)	 or	mammalian	 target	 of	 rapa‐
mycin	inhibitors.	One	important	observation,	the	use	of	everolimus	
with	reduced	tacrolimus	exposure	helped	to	preserve	renal	function	
after	3‐year	follow	up	which	indicated	that	consideration	should	be	
given	to	minimize	the	dose	of	CNIs	or	switch	to	MMF	or	everolimus	
for these patients.55,56
This	study	has	exclusively	focused	on	the	effectiveness	and	tol‐
erability	of	DAA	 treatment.	Thus,	 a	 control	 group	 is	not	 included,	
such	 as	 patients	 treated	with	DAAs	 before	 LT	 or	 treated	with	 in‐
terferon	post	LT.	Thus,	without	such	a	control,	we	cannot	conclude	
whether	treatment	post	LT	has	any	advantage	than	treatment	prior	
to	 LT	 or	 interferon‐treated	 recipients.	 Besides,	most	 studies	were	
from	 developed	 regions,	 including	 North	 American	 or	 European	
countries.	Hence,	multiregional	studies	are	still	needed	to	substan‐
tiate the comprehensive information for better clinical guidance 
globally.	Finally,	 the	field	of	HCV	treatment	 is	a	dynamic	and	con‐
stantly	changing	landscape.	A	number	of	new	agents	or	combination	
approaches may still in clinical trials or just licensed.
In	 summary,	 our	 results	 support	DAAs	 as	 treatment	 for	 eradi‐
cating	GT1	HCV	recurrence	in	 liver	transplant	recipients.	They	are	
highly	effective	and	well‐tolerated.	However,	 fine‐tuning	 is	essen‐
tial	for	achieving	the	optimal	outcome,	given	considerations	of	drug	
availability,	potential	drug‐drug	interactions,	the	fibrotic	or	cirrhotic	
stage of the patients and regional/social factors.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
     |  11 of 12LIU et aL.
AUTHORS'  CONTRIBUTIONS
QP	conceived	and	designed	 the	 research,	 analyzed	 the	data,	per‐
formed	statistical	analysis,	handled	funding	and	supervision,	drafted	
the	article,	and	made	critical	revision	of	the	article	for	important	in‐
tellectual	content.	JL	and	BM	conceived	and	designed	the	research,	
acquired	the	data,	performed	statistical	analysis,	drafted	the	article,	
and made critical revision of the article for important intellectual 
content.	WC	 conceived	 and	 designed	 the	 research,	 acquired	 the	
data,	 and	made	critical	 revision	of	 the	 article	 for	 important	 intel‐
lectual	content.	WB	performed	the	literature	research.	ML	acquired	
and	analyzed	the	data,	and	made	critical	revision	of	the	article	for	
important	intellectual	content.	MP	conceived	and	designed	the	re‐
search,	analyzed	the	data,	performed	statistical	analysis,	and	made	
critical revision of the article for important intellectual content.
ORCID
Qiuwei Pan  https://orcid.org/0000‐0001‐9982‐6184 
REFERENCES
	 1.	 Brown	 RS.	 Hepatitis	 C	 and	 liver	 transplantation.	 Nature. 
2005;436(7053):973‐978.
	 2.	 Gane	 EJ,	 Portmann	 BC,	Naoumov	NV,	 et	 al.	 Long‐term	 outcome	
of hepatitis C infection after liver transplantation. N Engl J Med. 
1996;334(13):815‐820.
	 3.	 Gane	 E.	 The	 natural	 history	 and	 outcome	 of	 liver	 transplan‐
tation	 in	 hepatitis	 C	 virus‐infected	 recipients.	 Liver Transpl. 
2003;9(11):S28‐S34.
	 4.	 Berenguer	M,	Ferrell	L,	Watson	J,	et	al.	HCV‐related	fibrosis	pro‐
gression following liver transplantation: increase in recent years. J 
Hepatol.	2000;32(4):673‐684.
	 5.	 Gane	EJ,	Agarwal	K.	Directly	acting	antivirals	(DAAs)	for	the	treat‐
ment of chronic hepatitis C virus infection in liver transplant patients: 
"a flood of opportunity". Am J Transplant.	2014;14(5):994‐1002.
	 6.	 Berenguer	 M,	 Palau	 A,	 Aguilera	 V,	 Rayon	 JM,	 Juan	 FS,	 Prieto	
M.	 Clinical	 benefits	 of	 antiviral	 therapy	 in	 patients	 with	 recur‐
rent hepatitis C following liver transplantation. Am J Transplant. 
2008;8(3):679‐687.
	 7.	 Garg	V,	van	Heeswijk	R,	Lee	JE,	Alves	K,	Nadkarni	P,	Luo	X.	Effect	of	
telaprevir	on	the	pharmacokinetics	of	cyclosporine	and	tacrolimus.	
Hepatology.	2011;54(1):20‐27.
	 8.	 Hulskotte	 E,	 Gupta	 S,	 Xuan	 F,	 et	 al.	 Pharmacokinetic	 interaction	
between the hepatitis C virus protease inhibitor boceprevir and 
cyclosporine and tacrolimus in healthy volunteers. Hepatology. 
2012;56(5):1622‐1630.
	 9.	 Hull	MW,	Yoshida	EM,	Montaner	JS.	Update	on	current	evidence	
for	hepatitis	C	therapeutic	options	in	HCV	mono‐infected	patients.	
Curr Infect Dis Rep.	2016;18(7):22.
	10.	 Nguyen	LH,	Nguyen	MH.	Systematic	review:	Asian	patients	with	chronic	
hepatitis C infection. Aliment Pharmacol Ther.	2013;37(10):921‐936.
	11.	 Kao	JH,	Ahn	SH,	Chien	RN,	et	al.	Urgency	to	treat	patients	with	chronic	
hepatitis	C	in	Asia.	J Gastroenterol Hepatol.	2017;32(5):966‐974.
	12.	 Messina	 JP,	 Humphreys	 I,	 Flaxman	 A,	 et	 al.	 Global	 distribu‐
tion and prevalence of hepatitis C virus genotypes. Hepatology. 
2015;61(1):77‐87.
	13.	 Jackson	WE,	Hanouneh	M,	Apfel	T,	et	al.	Sofosbuvir	and	simeprevir	
without ribavirin effectively treat hepatitis C virus genotype 1 in‐
fection	after	liver	transplantation	in	a	two‐center	experience.	Clin 
Transplant.	2016;30(6):709‐713.
	14.	 O'Leary	JG,	Fontana	RJ,	Brown	K,	et	al.	Efficacy	and	safety	of	sime‐
previr and sofosbuvir with and without ribavirin in subjects with 
recurrent genotype 1 hepatitis C postorthotopic liver transplant: 
the	randomized	GALAXY	study.	Transpl Int.	2017;30(2):196‐208.
	15.	 Punzalan	CS,	Barry	C,	Zacharias	I,	et	al.	Sofosbuvir	plus	simeprevir	
treatment of recurrent genotype 1 hepatitis C after liver transplant. 
Clin Transplant.	2015;29(12):1105‐1111.
	16.	 Crittenden	NE,	Buchanan	LA,	Pinkston	CM,	et	al.	Simeprevir	and	
sofosbuvir with or without ribavirin to treat recurrent genotype 1 
hepatitis C virus infection after orthotopic liver transplantation. 
Liver Transpl.	2016;22(5):635‐643.
	17.	 Pungpapong	 S,	 Aqel	 B,	 Leise	 M,	 et	 al.	 Multicenter	 experience	
using simeprevir and sofosbuvir with or without ribavirin to 
treat hepatitis C genotype 1 after liver transplant. Hepatology. 
2015;61(6):1880‐1886.
	18.	 Khemichian	S,	Lee	B,	Kahn	J,	et	al.	Sofosbuvir	and	simeprevir	ther‐
apy for recurrent hepatitis C infection after liver transplantation. 
Transplant Direct.	2015;1(6):e21.
	19.	 Lutchman	G,	Nguyen	NH,	Chang	CY,	et	al.	Effectiveness	and	toler‐
ability	of	simeprevir	and	sofosbuvir	in	nontransplant	and	post‐liver	
transplant patients with hepatitis C genotype 1. Aliment Pharmacol 
Ther.	2016;44(7):738‐746.
	20.	 Brown	RS	Jr,	O'Leary	JG,	Reddy	KR,	et	al.	Interferon‐free	therapy	
for	genotype	1	hepatitis	C	in	liver	transplant	recipients:	Real‐world	
experience	from	the	hepatitis	C	therapeutic	registry	and	research	
network.	Liver Transpl.	2016;22(1):24‐33.
	21.	 Ueda	Y,	 Ikegami	T,	Akamatsu	N,	 et	 al.	Treatment	with	 sofosbuvir	
and	 ledipasvir	 without	 ribavirin	 for	 12	 weeks	 is	 highly	 effective	
for recurrent hepatitis C virus genotype 1b infection after living 
donor	 liver	 transplantation:	 a	 Japanese	multicenter	 experience.	 J 
Gastroenterol.	2017;52(8):986‐991.
	22.	 Elfeki	 MA,	 Abou	 Mrad	 R,	 Modaresi	 Esfeh	 J,	 et	 al.	 Sofosbuvir/
Ledipasvir	 Without	 Ribavirin	 Achieved	 High	 Sustained	 Virologic	
Response	 for	Hepatitis	C	Recurrence	After	Liver	Transplantation:	
Two‐Center	Experience.	Transplantation.	2017;101(5):996‐1000.
	23.	 Shoreibah	 M,	 Orr	 J,	 Jones	 D,	 Zhang	 J,	 Venkata	 K,	 Massoud	 O.	
Ledipasvir/sofosbuvir	without	ribavirin	is	effective	in	the	treatment	
of	recurrent	hepatitis	C	virus	infection	post‐liver	transplant.	Hepatol 
Int.	2017;11(5):434‐439.
	24.	 Ikegami	T,	Ueda	Y,	Akamatsu	N,	et	al.	Asunaprevir	and	daclatasvir	
for	recurrent	hepatitis	C	after	liver	transplantation:	A	Japanese	mul‐
ticenter	experience.	Clin Transplant.	2017;31(11).
	25.	 Honda	M,	Sugawara	Y,	Watanabe	T,	et	al.	Outcomes	of	treatment	
with daclatasvir and asunaprevir for recurrent hepatitis C after liver 
transplantation. Hepatol Res.	2017;47(11):1147‐1154.
	26.	 Herzer	 K,	 Papadopoulos‐Kohn	 A,	 Walker	 A,	 et	 al.	 Daclatasvir,	
Simeprevir	 and	 Ribavirin	 as	 a	 Promising	 Interferon‐Free	 Triple	
Regimen	 for	 HCV	 Recurrence	 after	 Liver	 Transplant.	 Digestion. 
2015;91(4):326‐333.
	27.	 Forns	X,	Berenguer	M,	Herzer,	et	al.	Efficacy,	safety,	and	pharmacoki‐
netics	of	simeprevir,	daclatasvir,	and	ribavirin	in	patients	with	recurrent	
hepatitis C virus genotype 1b infection after orthotopic liver transplan‐
tation:	The	Phase	II	SATURN	study.	Transpl Infect Dis.	2017;19(3).
	28.	 Kwo	 PY,	 Mantry	 PS,	 Coakley	 E,	 et	 al.	 An	 interferon‐free	 anti‐
viral	 regimen	 for	 HCV	 after	 liver	 transplantation.	 N Engl J Med. 
2014;371(25):2375‐2382.
	29.	 Rousselet	 MC,	 Bedossa	 P,	 Pilette	 C,	 Oberti	 F,	 Cales	 P.	 Metavir	
score reflects liver fibrosis in chronic alcoholic diseases. Hepatology. 
1999;30(4):586a–586a.
	30.	 Nguyen	NH,	Yee	BE,	Chang	C,	et	al.	Tolerability	and	effectiveness	of	
sofosbuvir	and	simeprevir	in	the	post‐transplant	setting:	systematic	re‐
view	and	meta‐analysis.	BMJ Open Gastroenterol.	2016;3(1):e000066.
	31.	 Lim	SG,	Aghemo	A,	Chen	PJ,	et	al.	Management	of	hepatitis	C	virus	
infection	in	the	Asia‐Pacific	region:	an	update.	Lancet Gastroenterol 
Hepatol.	2017;2(1):52‐62.
12 of 12  |     LIU et aL.
	32.	 Berenguer	M,	Prieto	M,	Rayon	JM,	et	al.	Natural	history	of	clinically	
compensated	 hepatitis	 C	 virus‐related	 graft	 cirrhosis	 after	 liver	
transplantation. Hepatology.	2000;32(4	Pt	1):852‐858.
	33.	 Carrion	 JA,	 Navasa	 M,	 Forns	 X.	 Retransplantation	 in	 patients	
with hepatitis C recurrence after liver transplantation. J Hepatol. 
2010;53(5):962‐970.
	34.	 European	Association	for	the	Study	of	the	Liver.	Electronic	address	
eee.	EASL	Recommendations	on	Treatment	of	Hepatitis	C	2016.	J 
Hepatol	2017;	66(1):	153–194.
	35.	 Perumpail	 RB,	Wong	RJ,	Ha	 LD,	 et	 al.	 Sofosbuvir	 and	 simeprevir	
combination therapy in the setting of liver transplantation and he‐
modialysis. Transpl Infect Dis.	2015;17(2):275–278.
	36.	 Manns	M,	Samuel	D,	Gane	EJ,	et	al.	Ledipasvir	and	sofosbuvir	plus	
ribavirin in patients with genotype 1 or 4 hepatitis C virus infection 
and	advanced	liver	disease:	a	multicentre,	open‐label,	randomised,	
phase 2 trial. Lancet Infect Dis.	2016;16(6):685–697.
	37.	 Lok	 AS,	 Gardiner	 DF,	 Lawitz	 E,	 et	 al.	 Preliminary	 study	 of	
two antiviral agents for hepatitis C genotype 1. N Engl J Med. 
2012;366(3):216–224.
	38.	 Fujii	Y,	Uchida	Y,	Mochida	S.	Drug‐induced	 immunoallergic	hepa‐
titis during combination therapy with daclatasvir and asunaprevir. 
Hepatology.	2015;61(1):400–401.
	39.	 Feld	JJ,	Hoofnagle	JH.	Mechanism	of	action	of	interferon	and	riba‐
virin in treatment of hepatitis C. Nature.	2005;436(7053):967–972.
	40.	 Thomas	 E,	 Ghany	MG,	 Liang	 TJ.	 The	 application	 and	mechanism	
of action of ribavirin in therapy of hepatitis C. Antiviral Chem 
Chemother.	2012;23(1):1–12.
	41.	 Gentile	 I,	 Borgia	 F,	 Buonomo	AR,	 Castaldo	G,	 Borgia	G.	 A	 novel	
promising therapeutic option against hepatitis C virus: an oral nu‐
cleotide	 NS5B	 polymerase	 inhibitor	 sofosbuvir.	 Curr Med Chem. 
2013;20(30):3733–3742.
	42.	 Fried	MW.	Side	effects	of	therapy	of	hepatitis	C	and	their	manage‐
ment. Hepatology.	2002;36(5	Suppl	1):S237–S244.
	43.	 Saab	S,	Greenberg	A,	 Li	 E,	 et	 al.	 Sofosbuvir	 and	 simeprevir	 is	 ef‐
fective for recurrent hepatitis C in liver transplant recipients. Liver 
International.	2015;35(11):2442–2447.
	44.	 Barri	YM,	Sanchez	EQ,	Jennings	LW,	et	al.	Acute	kidney	injury	fol‐
lowing liver transplantation: definition and outcome. Liver Transpl. 
2009;15(5):475–483.
	45.	 Ojo	AO,	Held	PJ,	Port	FK,	et	al.	Chronic	renal	failure	after	transplan‐
tation of a nonrenal organ. N Engl J Med.	2003;349(10):931–940.
	46.	 Gambato	M,	Lens	S,	Navasa	M,	Forns	X.	Treatment	options	in	pa‐
tients	with	decompensated	cirrhosis,	pre‐	and	post‐transplantation.	
J Hepatol.	2014;61(1	Suppl):S120–S131.
	47.	 Weber	ML,	Ibrahim	HN,	Lake	JR.	Renal	dysfunction	in	liver	trans‐
plant recipients: evaluation of the critical issues. Liver Transpl. 
2012;18(11):1290–1301.
	48.	 Husing	A,	Kabar	I,	Schmidt	HH,	Heinzow	HS.	Hepatitis	C	in	special	
patient cohorts: new opportunities in decompensated liver cirrho‐
sis,	end‐stage	renal	disease	and	transplant	medicine.	 Int J Mol Sci. 
2015;16(8):18033–18053.
	49.	 Teegen	EM,	Durr	M,	Maurer	MM,	et	al.	Evaluation	of	histological	
dynamics,	kidney	function	and	diabetes	in	liver	transplant	patients	
after	 antiviral	 treatment	 with	 direct‐acting	 antivirals:	 Therapy	 of	
HCV‐recurrence.	Transpl Infect Dis. 2018;e13020.
	50.	 Glead	Siences	Inc	These	highlights	do	not	include	all	the	information	
needed	to	use	SOVALDI	safely	and	effectively.	See	full	prescribing	
information	 for	 SOVALDI.<http://www.gilead.com/~/media/Files/
pdfs/medicines/liverdisease/sovaldi/sovaldi_pi.pdf>	2017.08.02.
	51.	 Saxena	V,	Koraishy	FM,	Sise	ME,	et	al.	Safety	and	efficacy	of	so‐
fosbuvir‐containing	regimens	 in	hepatitis	C‐infected	patients	with	
impaired renal function. Liver International.	2016;36(6):807–816.
	52.	 Dumortier	 J,	 Bailly	 F,	 Pageaux	GP,	 et	 al.	 Sofosbuvir‐based	 antivi‐
ral therapy in hepatitis C virus patients with severe renal failure. 
Nephrol Dial Transplant.	2017;32(12):2065–2071.
	53.	 Kim	WR,	 Smith	 JM,	 Skeans	MA,	 et	 al.	OPTN/SRTR	 2012	 annual	
data report: liver. Am J Transplant.	2014;14(Suppl	1):69–96.
	54.	 Flechner	 SM,	 Kobashigawa	 J,	 Klintmalm	G.	 Calcineurin	 inhibitor‐
sparing regimens in solid organ transplantation: focus on improving 
renal	function	and	nephrotoxicity.	Clin Transplant.	2008;22(1):1–15.
	55.	 Saliba	F,	De	Simone	P,	Nevens	F,	et	al.	Renal	function	at	two	years	in	
liver transplant patients receiving everolimus: results of a random‐
ized,	multicenter	study.	Am J Transplant.	2013;13(7):1734–1745.
	56.	 Sterneck	M,	Kaiser	GM,	Heyne	N,	et	al.	Everolimus	and	early	calci‐
neurin	inhibitor	withdrawal:	3‐year	results	from	a	randomized	trial	
in liver transplantation. Am J Transplant.	2014;14(3):701–710.
SUPPORTING INFORMATION
Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article.	
How to cite this article:	Liu	J,	Ma	B,	Cao	W,	et	al.	Direct‐acting	
antiviral agents for liver transplant recipients with recurrent 
genotype 1 hepatitis C virus infection: Systematic review and 
meta‐analysis.	Transpl Infect Dis. 2019;21:e13047. https://doi.
org/10.1111/tid.13047
